INTRODUCTION
Meningioma represents the most common primary brain tumor, accounting for greater than one-third of all intracranial lesions. 1 Although the majority are benign and often can be treated conservatively, atypical and malignant meningiomas are aggressive lesions prone to local recurrence, are often recalcitrant to salvage therapies, and can lead to decreased survival. [2] [3] [4] These lesions warrant more aggressive treatment approaches. Patients with malignant meningiomas typically are treated with maximal surgical resection and adjuvant radiotherapy (RT). However, the optimal treatment of patients with atypical meningiomas is less clear. Due to the low incidence of such lesions, there are limited prospective data available and thus a retrospective, facility-based analysis was undertaken.
The primary goal of the current study was to: 1) identify, with adequate statistical power, the effect of surgery and RT on long-term outcomes of patients with atypical and malignant meningiomas; and 2) present a modern update to prior population-based meningioma studies 5, 6 providing long-term outcome estimates. To achieve these goals, the National Cancer Data Base (NCDB) was queried.
MATERIALS AND METHODS

Data Source
The NCDB of the American Cancer Society and the American College of Surgeons Commission on Cancer is a nationwide, facility-based oncology registry and outcomes database, incorporating approximately 70% of all newly diagnosed patients in the United States. 7 Data are coded and reported according to a rigorous and standardized, nationally established protocol including detailed information regarding patient demographics and tumor staging as well as treatment. The current study was exempt from institutional review board approval, with no patient, provider, or hospital identifiers used or identified.
Study Population
The study cohort included all patients diagnosed with and treated for meningioma from 2004 through 2014. Inclusion was based on a primary site diagnosis of atypical and malignant meningioma as previously described (including International Classification of Diseases for Oncology, 3rd Edition [ICD-O-3] codes 9539/1 for atypical lesions and 9530/3 for malignant lesions) 5 ; histological confirmation was required. Patients were excluded from the outcome analysis if there was missing/unknown information regarding: 1) receipt of surgery or RT; 2) extent of surgical resection (including if "unknown extent" or "not otherwise specified"); 3) timing of RT; or 4) if RT was delivered 6 months from the time of the histologic diagnosis (to omit any cases of salvage treatment for recurrent or progressive disease). The number and survival rate for patients with benign meningiomas were estimated during the study period for population-based outcome estimates; however, all further analyses were restricted to patients with higher grade lesions.
Patient, Treatment, and Tumor Characteristics
The extent of surgery was stratified into gross (macroscopic) total resection (GTR) or non-GTR. Incorporating adjuvant RT, patients were split into groups incorporating each possible treatment approach/strategy: 1) GTR alone; 2) GTR with RT; 3) non-GTR alone; and 4) non-GTR with RT.
Recorded patient and tumor characteristics included tumor size, race/ethnicity (non-Hispanic white, nonHispanic black, Hispanic, Asian, and other/unknown), income quartiles, education quartiles, insurance status (Medicaid/uninsured, Medicare/private insurance, and unknown), Charlson-Deyo Comorbidity Score, hospital type (academic or community), distance from hospital, and year of diagnosis. The Charlson-Deyo Comorbidity Score was based on the International Classification of Diseases, Ninth Revision, codes for chronic disease and was categorized as 0, 1, or 2. 8 
Statistical Analysis
The significance of differences in all-cause mortality was assessed using Kaplan-Meier survival curves with log-rank tests of significance. Cox proportional hazards multivariate regressions were used to estimate mortality hazard ratios (HRs). Cox models were estimated using standard errors to adjust for clustering of cases within hospitals. Multivariate logistic regression was used to compare variables that predicted the receipt of adjuvant RT. All analyses Figure 1 . Kaplan-Meier survival curves by tumor histology. The log-rank test for equality of survivor functions comparing all 3 histologies was found to be statistically significant at P<.0001.
were performed with Stata statistical software (version 14; StataCorp LLC, College Station, Texas).
RESULTS
Patient, Tumor, and Survival Characteristics
A total of 70,092 patients were diagnosed with histologically confirmed meningioma from 2004 to 2014 (Table  1) ; of these, 60,345 (86.1%) had benign meningiomas, 7811 (11.1%) had atypical meningiomas, and 1936 (2.8%) had malignant meningiomas. Women represented the majority of cases for all histologies, including 72% of benign, 55.5% of atypical, and 58.1% of malignant lesion cases. Full patient and tumor characteristics are listed in Table 1 .
The 5-year overall survival rate was 85.5% for benign lesions, 75.9% for atypical lesions, and 55.4% for malignant lesions. Figure 1 shows the Kaplan-Meier survival curves for all 3 histologies, demonstrating a significant difference in overall survival (P<.0001) (Fig. 1) . Table 2 lists 2-year and 5-year overall survival by histology.
Outcomes by Treatment Approach
An analysis of treatment outcomes was conducted on 4157 patients (3529 with atypical meningioma and 628 with malignant meningioma) who fully met the inclusion criteria (ie, those with complete information regarding surgical extent and timing of RT). For patients for whom full RT details were available, the median dose was 54 Gy, with 47.6% of patients undergoing intensity-modulated RT.
For patients with atypical meningiomas, both GTR and RT were shown to be significant factors of survival on multivariate analysis, both independently and especially in unison (HR for GTR plus RT: 0.47; P 5 .002). In terms of magnitude, this was the most important factor found for improved survival (Table 3 ). For patients with malignant meningiomas, the same trend persisted but without statistical significance (HR for GTR plus RT: 0.67; P 5 .174). Other variables found to be associated with worse survival included male sex, older age, nonHispanic black race, higher Charlson-Deyo Comorbidity Score, and being treated at a community hospital. For patients with malignant meningiomas, only older age was found to be statistically significant.
The 5-year survival rate was greatest in the group of patients who received GTR plus adjuvant RT, both for atypical meningiomas (88.1% survival rate) and malignant meningiomas (60.7% survival rate) ( Table 4 ). Figure  2 shows survival curves for patients with atypical and malignant meningiomas, respectively.
Predictors of Receiving Adjuvant RT
On multivariate logistic regression, undergoing GTR for the treatment of atypical meningioma was associated with a significantly lower likelihood of receiving RT (odds ratio [OR], 0.57; P<.001), whereas no such correlation existed for malignant meningiomas (OR, 1.00; P 5 .991). For patients with atypical meningiomas, other variables included smaller tumor size, age 80 years, and a higher Charlson-Deyo Comorbidity Score. For patients with malignant meningiomas, only smaller tumor size was found to be associated with a lower likelihood of receipt of RT.
DISCUSSION
The results of the current study demonstrate that GTR and adjuvant RT are highly associated with improved survival, especially for patients with atypical meningiomas. On multivariate analysis, this was found to be the most important factor. Furthermore, we report the long-term survival outcomes by histology from our populationbased cohort, with a 5-year survival rate of 85.5% for patients with benign disease, 75.9% for patients with atypical disease, and 55.4% for patients with malignant disease. To our knowledge, the current series represents the largest patient cohort of meningioma outcomes published to date, both in total and especially for malignant and atypical lesions.
Before this report, 2 prior population-based studies included a more recent Surveillance, Epidemiology, and End Results (SEER) analysis of 575 patients with atypical meningiomas and 64 patients with malignant meningiomas and an older NCDB study (including 165 atypical and 771 malignant lesions). 5, 6 In the first study, GTR was associated with improved survival but RT was not. 5 In the second study, surgery without RT for malignant meningiomas led to improved outcomes but for patients with atypical meningiomas, there was no difference noted among any treatment groups. 6 It is possible that these conclusions may have been sharply limited by the smaller sample size (both studies had < 1000 higher grade cases) as opposed to the much higher numbers in the current analysis.
The data from the current study also provide an update on 5-year survival with meningiomas. Per prior estimates, the 5-year survival rate was reported to be 70.1%, 74.5%, and 54.6%, respectively, for patients with benign, atypical, and malignant meningiomas. 5 These rates compare with the 5-year survival rates in the current study of 85.5%, 75.9%, and 55.4%, respectively, for patients with benign, atypical, and malignant meningiomas. The similarities for atypical and malignant meningiomas speak to the strength of comparison of these 2 studies. However, the 5-year survival rate was likely to be higher for patients with benign lesions in the current Abbreviations: 95% CI, 95% confidence interval; GTR, gross (macroscopic) total resection; HR, hazard ratio; RT, radiotherapy. a Controlled for the same covariates as above (excluding independent effects of RT and surgical resection).
analysis because cases were histologically confirmed (excluding presumed cases) and this finding supported by various clinical studies with 5-year survival rates ranging from 83% to 87%. 5, [9] [10] [11] It is important to note that these numbers (and all patients in the current study) reflect the revised histopathologic grading criteria proposed by the World Health Organization (WHO) in 2000 (ie, using necrosis as a feature of atypical lesions, etc). 12 The treatment paradigms for benign (WHO grade 1) and malignant (WHO grade 3) meningiomas generally are agreed upon. Benign lesions often can be observed, even after subtotal surgical resection (in select cases), with aggressive extirpation and RT reserved for patients with recurrent and symptomatic lesions. 13 Patients with malignant lesions generally are treated with maximal surgical resection followed by RT. 14 Indeed, in the current study cohort, we found no correlation between the degree of surgical resection and the likelihood of RT for patients with malignant meningiomas (OR, 1.00; P 5 .991).
However, there is less clarity regarding the optimal treatment of patients with atypical meningiomas (WHO grade 2). In the absence of yet-to-result prospective studies, national guidelines (ie, National Comprehensive Cancer Network) continue to recommend adjuvant RT only as a consideration in this setting (as opposed to a recommendation for patients with malignant lesions). 15 As such, GTR often precludes adjuvant RT; in the current study, the likelihood of RT after GTR had an OR of 0.57 (P<.001). However, the results of the current study give credence to institutional reports that found a significant benefit in combining RT with maximal surgical resection. 16 After GTR was performed among patients with atypical meningioma, Aghi et al noted that 28% of patients developed disease recurrence when followed postoperatively as opposed to none of the patients who received adjuvant RT. 17 Table 5 shows a summary of the literature, with the majority of studies demonstrating an improvement in outcomes with RT. [17] [18] [19] [20] [21] [22] [23] [24] [25] There also are conflicting institutional and pooled reports. For example, Graffeo et al found no benefit with adjuvant RT in 69 patients who underwent GTR; an accompanying metaanalysis/review also did not reach statistical significance (albeit it did report improved absolute progression-free and overall survival) for RT after GTR. 18 An important difference in the current study is that the sample size was 3 times larger, which perhaps provided enough power to allow for significance to materialize. The preliminary results (in abstract form) of the phase 2 NRG/Radiation Therapy Oncology Group (RTOG) 0539 study found that a combination of surgery/RT led to significantly improved progression-free survival in a group of patients treated for recurrent grade 1 lesions and completely resected atypical lesions. 26 This will be tested in the future with NRG Oncology protocol BN-003 and the ongoing Radiation versus Observation following surgical resection of Atypical Meningioma (ROAM)/European Organization for Research and Treatment of Cancer (EORTC)-1308 trial, for which, based on the results of the current study, we would support patient enrollment for the evaluation of disease-free-survival. 27 Although studies to date have demonstrated improvement in disease control with RT, the results of the current study (which we believe to have enough patients and follow-up) actually suggested that this improved control is likely to lead to improved survival in the future.
On multivariate analysis, the current study data also demonstrated poorer survival in African American patients. This was most apparent for patients with atypical meningiomas, but trended similarly in patients with malignant lesions. Furthermore, the poorer survival could not be attributed to a lower likelihood of receiving RT (Table 6) . 17, [19] [20] [21] [22] [23] [24] [25] These are interesting findings; epidemiologic studies have shown that meningiomas occur more often in African American individuals and without a significant sex disparity. 28, 29 The data from the current study indicate the possibility that such lesions also may behave more aggressively. Although such findings currently are only hypothesis-generating, we believe they deserve more investigation/confirmation in the future.
There are several limitations to the current analysis. First, the NCDB is a facility-based registry restricted to prespecified variables and constraints. This limits the amount of disease-specific and toxicity endpoints that can be analyzed, including functional and cognitive outcomes, as well as detailed histopathologic and recurrence data. Second, treatment-related outcomes could be affected by selection bias (ie, none of these patients were prospectively assigned a treatment approach). Although every attempt was made to control for other effectors through multivariate modeling, it is not possible to completely control for such bias. For example, neither the performance status nor active comorbidities of the patients were available, although we did account for the standardized CharlsonDeyo Comorbidity Score into our modeling. Finally, because of the nature of such a study design, important surgical and RT metrics were missing. For example, it is impossible to know dosimetric and volumetric parameters for RT that, in the modern era of image-guided highly conformal RT, are paramount for ensuring optimal treatment. In addition, the far fewer malignant meningiomas herein limited statistical power in this setting, even though the combination of GTR plus RT continued to demonstrate best absolute survival. Despite such limitations, the results of the current study demonstrate that aggressive treatment of patients with atypical meningiomas with maximal surgical resection and adjuvant RT is highly associated with improved long-term survival. The results also indicate, as per common practice trends and national guidelines, that a complete surgical resection is associated with a lower likelihood of receiving RT. In keeping with accumulating evidence, these data would argue for routine RT after surgical resection of atypical meningiomas. Second, this Abbreviations: 95% CI, 95% confidence interval; GTR, gross (macroscopic) total resection; OR, odds ratio; RT, radiotherapy.
population-based cohort demonstrated significant differences and separation of long-term overall survival based on meningioma grade, thereby validating earlier findings and grading categorization. Finally poorer survival outcomes were noted among African American patients, a finding that requires further study in the future.
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